Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6335447 | FERRER INTERNACIONAL | Quinolonecarboxylic acid derivatives or salts thereof |
Nov, 2023
(7 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9399014 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Dec, 2029
(6 years from now) | |
US9180200 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Jan, 2032
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 11, 2022 |
NCE-1 date: 2021-12-11
Market Authorisation Date: 11 December, 2017
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: CREAM;TOPICAL
5
United States
4
European Union
3
Korea, Republic of
2
Mexico
2
Chile
2
Taiwan, Province of China
2
Japan
2
Canada
1
Denmark
1
Australia
1
Hong Kong
1
Slovenia
1
Russia
1
Philippines
1
Uruguay
1
Argentina
1
Brazil
1
Portugal
1
Cyprus
1
Spain
1
Netherlands
1
Poland
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic